Aikido Pharma Inc AIKI:NASDAQ

AIkido Pharma (AIKI) said Thursday it secured an additional US patent covering claims for its pancreatic cancer drug DHA-dFdC.

The new patent is valid until May 2035.

The biotechnology firm also said it filed a continuation patent application to expand the patent coverage to other aspects of the drug.

Meanwhile, AIkido said it entered into another deal with its contract manufacturer, Parimer Scientific, to use a newly developed manufacturing process for DHA-dFdC.

The new manufacturing process will enable the production of "several thousand milligrams" of the drug for use in formulation development and stability studies, the company said.

AIkido shares were 1.4% higher in morning trading.